References
- Brannon-Peppas L, Blanchette JO. 2004. Nanoparticle and targeted systems for cancer therapy. Adv Drug Deliv Rev 56:1649–1659.
- Brigger I, Dubernet C, Couvreur P. 2002. Nanoparticles in cancer therapy and diagnosis. Adv Drug Deliv Rev 54:631–651.
- Couvreur P, Kante B, Roland M, Guiot P, Bauduin P, Speiser P. 1979. Polycyanoacrylate nanocapsules as potential lysosomotropic carriers: preparation, morphological and sorptive properties. J Pharm Pharmacol 31:331–332.
- Cui Z, Sun Y, Liu X, Ju F, Chen Q, Gao W, Wei H. 2013. Preparation and evaluations in vitro of Oxaliplatin polylactic acid nanoparticles. Artif Cells Nanomed Biotechnol. 41:227–231.
- Feng SS, Huang GF. 2001. Effects of emulsifiers on the controlled release of paclitaxel (Taxo1) from nanospheres of biodegradable polymers. J Control Release 71:53–69.
- Gref R, Lück M, Quellec P, Marchand M, Dellacherie E, Harnisch S, et al. 2000. Stealth corona-core nanoparticles surface modified by polyethylene glycol (PEG): influences of the corona (PEG chain length and surface density) and of the core composition on phagocytic uptake and plasma protein adsorption. Colloids Surf B Biointerfaces. 18:301–313.
- Kim K, Yu M, Zong X, Chiu J, Fang D, Seo YS, et al. 2003. Control of degradation rate and hydrophilicity in electrospun non-woven poly (D, L-lactide) nanofiber scaffolds for biomedical applications. Biomaterials 24:4977–4985.
- Peracchia MT, Fattal E, Desmaele D, Besnard M, Noël JP, Gomis JM, et al. 1999. Stealth® PEGylated polycyanoacrylate nanoparticles for intravenous administration and splenic targeting. J Control Release 60:121–128.
- Schadlich A, Caysa H, Mueller T, Tenambergen F, Rose C, Göpferich A, et al. 2011. Tumor accumulation of NIR fluorescent PEG–PLA nanoparticles: Impact of particle size and human xenograft tumor model. ACS Nano 5:8710–8720.
- Vauthier C, Cabane B, Labarre D. 2008. How to concentrate nanoparticles and avoid aggregation. Eur J Pharm Biopharm 69:466–475.